期刊文献+

口服抗栓药预防非瓣膜性心房颤动患者卒中:美国心脏协会/美国卒中协会对医疗卫生专业人员的科学建议 被引量:4

Oral antithrombotic agents for the prevention of stroke in nonvalvular atrial fibrillation A Science Advisory for Healthcare Professionals From the American Heart Association/American Stroke Association
原文传递
导出
摘要 成年心房颤动(atrial fibrillation,AF)患者的卒中发生率存在很大差异,其范围为每年1%~20%(平均4.5%/年),取决于合并症和既往脑血管事件病史。卒中风险分层十分重要,因为用于降低AF相关性卒中发生率的抗栓药的主要风险是出血。对于华法林而言,这涉及到对出血风险(每年1%~12%)与缺血性事件风险的权衡,它通常被用于血栓栓塞风险最高的那些患者。
出处 《国际脑血管病杂志》 北大核心 2012年第12期881-892,共12页 International Journal of Cerebrovascular Diseases
  • 相关文献

参考文献58

  • 1Risk factors for stroke and efficacy of antithrombotic therapy in atrial fibrillation. Analysis of pooled data from five randomized controlled trials. Arch Intern Med, 1994, 154: 1449-1457.
  • 2Stroke Risk in Atrial Fibrillation Working Group. Independent predictors of stroke in patients with atrial fibrillation: a systematic review. Neurology, 2007, 69: 546-554.
  • 3Loewen P, Dahri K. Risk of bleeding with oral anticoagulants: an updated systematic review and performance analysis of clinical prediction rules. Ann Hematok 2011, 90: 1191-1200.
  • 4Goldstein LB, Bushnell CD, Adams RJ, et al; American Heart Association Stroke Council; Council on Cardiovascular Nursing; Council on Epidemiology and Prevention; Council for High Blood Pressure Research,; Council on Peripheral Vascular Disease, and Interdisciplinary Council on Quality of Care and Outcomes Research. Guidelines for the primary prevention of stroke: a ghdeline for healthcare professionals from the Armx'ican H"t Association/American Stroke Association. Stroke, 2011, 42: 517- 584.
  • 5Furie KL, Kasner SE, Adams RJ, et al; Arr'ican Heart Association Stroke Council, Council on Cardiovascular Nursing Council on Clinical Cardiology, and Interdisciplinary Council on Quality of Cea'e and Outcomes Research. Guidelines for the prevention of stroke in patients with stroke or transient ischerrhc attack: a guideline for healthcare professionals fi'om the Arm'rican Hart Association/American Stroke Association. Stroke, 2011, 42: 227-276.
  • 6Gage BF, van Walraven C, Pearce L, et al. Selecting patients with atrial fibrillation for anticoagulation: stroke risk stratification in patients taking aspirin. Circulation, 2004, 110: 2287-2292.
  • 7Gage BF, Waterman AD, Shannon W, et al. Validation of clinical classification schemes for predicting stroke: results from the National Registry of Atrial Fibrillation. JAMA, 2001, 285: 2864-2870.
  • 8Hart I(G, Halperin JL, Pearce LA, et al; Stroke Prevention in Atrial Fibrillation Investigators. Lessons from the Stroke Prevention in Atrial Fibrillation trials. Ann Intern Med, 2003, 138: 831-838.
  • 9Stroke Risk in Atria/Fibrillation Working Group. Comparison of 12 risk stratification scherms to predict stroke in patients with nonvalvul: atrial fibrillation. Stroke, 2008, 39: 1901-1910.
  • 10Go AS, Hylek EM, Chang Y, et al. Anticoagulation therapy for stroke prevention in atrial fibrillation: how well do randomized trials translate into clinical practice? JAMA, 2003, 290: 2685-2692.

同被引文献9

引证文献4

二级引证文献21

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部